Trial reportClinical and experimental medicine2025
A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study.
Trial report in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite receiving an annual influenza vaccination, lupus patients showed a decline in immunological responses for various reasons. This study aimed to assess immune responses after booster- (BD) and standard-dose (SD) quadrivalent influenza vaccine and the adverse events and incidence of influenza infection among lupus patients. A randomized controlled trial was conducted between March 2021 and May 2022 at Ramathibodi Hospital. All lupus patients were stratified into two groups depending on the depth of immunosuppressive therapy and randomized to receive either BD or SD. Hemagglutination inhibition assay (HAI) before vaccination and 4 weeks after completion of the vaccination series were assessed. The incidence of influenza infection and vaccine-associated adverse events were recorded. A total of 109 lupus patients completed the HAI analysis. 54/109 patients were in high- (HI), and 55/109 were in low-level immunosuppressive (LI) groups. Focusing at the rates to achieve HAI ≥ 1:160, in the LI group, the rates after SD were 85.5% for H1N1, 69.2% for H3N2/Hongkong, 82.8% for H3N2/Cambodia, 85.5% for B/Victoria, and 81.8% for B/Yamagata. After BD, the HAI titer rates of ≥ 1:160 cut point were increased in all strains, approaching 100%, similar to the HI group. There was one documented influenza infection during the 12-month follow-up period in LI who received SD. No serious adverse events associated with influenza vaccination were recorded. A booster dose of influenza vaccination may provide a higher HAI titer among lupus patients. The booster influenza vaccine regimen was considered safe in the BD group. Thai Clinical Trials Registry: TCTR20230610003.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.